Graph AI Raises $13.3M for Patient Safety Automation

Speed is cheap until a drug-safety case has to survive an inspection. The software can move an adverse-event report in seconds, but a safety team still needs to know where the evidence came from, what changed, who reviewed it, and why a decision deserves to stand.

Graph AI is financing that harder version of automation. The Pleasanton, California company announced a $13.3M Series A on September 10, 2026, led by Insight Partners with returning investor Bessemer Venture Partners participating.

The round arrives less than a year after Bessemer led Graph AI's $3M seed. Graph AI says the new capital will support expansion across the US and Europe while it extends Graph Safety from adverse-event intake and individual case processing into aggregate reporting and signal detection.

What Graph AI Is Building

Pharmacovigilance is the discipline through which drug companies collect, assess, and report safety information across a medicine's lifecycle. The work pulls evidence from emails, PDFs, structured feeds, literature, patient-support programs, and other channels, then asks specialists to turn that material into a reviewable case without losing the clinical context or regulatory clock around it.

Graph AI is trying to make that chain operate as one system. Its /intake module ingests, extracts, validates, classifies, deduplicates, and routes safety material, while /nucleus connects evidence, clinical reasoning, reviewer decisions, validation history, and submission-ready case states. The company says both modules are live with pharmaceutical and biotech customers.

The next modules push the platform beyond individual cases. Graph AI said /report, which automates aggregate safety reporting, is launching in September 2026, while /signal is being developed with design partners to identify patterns across cases. The broader roadmap also includes assurance and compliance functions intended to keep validation, audit trails, and regulatory timing inside the operating workflow.

Why Traceability Is the Product

AI can make a manual process faster while making accountability harder to locate. That trade becomes expensive in patient safety, where an answer may need to be reconstructed for a medical reviewer, quality team, auditor, or regulator long after the model produced it.

Graph Safety is designed around deterministic controls, validation layers, source traceability, human review, and end-to-end audit trails. The company describes a system in which critical decisions remain attributable and overridable, allowing automation to handle operational movement while safety professionals retain responsibility for clinical and regulatory judgment.

That design direction matches the wider regulatory conversation, although it does not amount to regulatory approval. The FDA's January 2025 draft guidance proposes a risk-based framework for evaluating the credibility of AI models used to support regulatory decisions, while CIOMS Working Group XIV argues that automation should free specialists from repetitive work without stripping human expertise from causality assessment.

The Evidence Behind the Round

Graph AI reports that live deployments reduced case-processing time from more than 3 hours to under 10 minutes, a decline of more than 90%, and lowered operating costs by up to 66%. Those figures are company-reported results rather than independently audited benchmarks, and Graph AI has not disclosed customer names or the number of organizations using the platform.

The claims still explain why this category attracts capital. A pharmaceutical company does not buy faster text generation for its own sake; it buys fewer manual handoffs, less rekeying, cleaner evidence continuity, and more expert time directed toward the decisions that affect patients and submissions. If those gains hold across deployments, the economic value comes from changing the operating model rather than adding another AI feature to an old workflow.

The investor mix reinforces that thesis. Insight principal Richard Matus pointed to the fragmented software and service landscape around patient-safety operations, while Bessemer partner Nithin Kaimal has made Graph AI part of a broader investment view around vertical AI challengers to labor-heavy services businesses.

The Team and the Expansion Job

Raghavendra Parvataraju leads Graph AI as CEO, with co-founder Vijay Ponukumati serving as CTO, Mohan Konyala as CPO, and Ashutosh Bordekar as CFO & COO. The company was founded in 2024 and maintains offices in Pleasanton and Hyderabad, giving it an operating base across the US and India as it prepares to expand further into the US and Europe.

That geography matters because the product has to travel through more than a sales pipeline. Pharmacovigilance systems sit inside different regulatory environments, data-governance expectations, safety organizations, and existing technology estates. Expansion will require Graph AI to prove that its platform can fit those local operating realities without breaking the traceability and oversight that make automation acceptable in the first place.

The $13.3M Series A gives the company room to build that commercial and technical capacity. It also raises the standard of evidence around the company's own claims, because the next customer will care less about a clean demo than about validation, implementation, interoperability, and the record left behind when the software makes work move faster.

What the Series A Signals

Graph AI's opportunity sits inside a broader shift from AI assistants toward vertical operating systems. In regulated markets, the winning product may not be the model that produces the most impressive isolated output. It may be the system that keeps data, decisions, controls, and people connected closely enough that an organization can trust the output at scale.

That is also the pressure inside this financing. Graph AI now has to convert company-reported deployment gains into repeatable customer evidence, carry /report and /signal into production, and expand across jurisdictions without turning the platform into the fragmented collection of modules it was built to replace. Patient safety teams will measure the company in recovered expert time, defensible decisions, and fewer broken handoffs, long after the funding headline has left the room.